Your session is about to expire
← Back to Search
Canakinumab for Clonal Cytopenia
Study Summary
This trial tests if a medicine can reduce the risk of cancer in people with low blood cell counts caused by a gene mutation.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had low blood counts for more than 4 months without a known reason.I am currently receiving treatment for another cancer.I have active tuberculosis.I have been diagnosed with MDS or another myeloid cancer.My tests show mutations in TET2, DMNT3A, or ASXL1 and another known mutation.My blood cancer has two or more specific genetic mutations.I have a weakened immune system or an infection.I need treatment that affects my immune system.I have had a bone marrow or organ transplant from another person.I have not received any live vaccines in the last 3 months.My condition does not meet the criteria for myelodysplastic syndromes.My cancer has a specific genetic mutation in the spliceosome.I do not have an active or recurring liver disease such as cirrhosis or hepatitis B/C.I am 18 or older with high-risk clonal cytopenia of undetermined significance.I haven't used any blood cell growth boosters in the last 4 weeks.I am able to care for myself and perform daily activities.My cancer has a specific genetic change in more than 5% of cells.My kidneys are working well.I do not have any blood cancer.I have an ongoing infection or often get infections.I have high blood pressure and am taking steps to manage it.I have mutations in TET2, DMNT3A, or ASXL1 genes above 10%.
- Group 1: ARM I (canakinumab)
- Group 2: ARM II (placebo)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How detrimental is the consumption of ARM I (canakinumab) to a patient's health?
"Our team at Power believes that ARM I (canakinumab) has a degree of safety which is rated as 2 on the 1 to 3 scale. This conclusion was drawn from Phase 2 data, meaning there are some studies confirming its safety but not any related to efficacy."
How many participants is the research team recruiting for this scientific endeavor?
"Affirmative. According to clinicaltrials.gov, this investigation is currently recruiting participants and was first published on January 1st 2023 with the most recent update occurring December 12th 2022. The study needs 110 patients between one site."
Is recruitment of research participants still open for this experiment?
"Correct. According to the clinicaltrials.gov portal, this medical trial is actively enrolling patients. It was first published on January 1st 2023 and was last updated on December 12th 2022 - with 110 patients required at a single site."
Share this study with friends
Copy Link
Messenger